354P Sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer patients: A multicenter real-world updated analysis
R. Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Pantano(Università Campus Bio-Medico), L. Del Mastro, Alessandro Rizzo(Istituto Tumori Bari), Andrea Botticelli(Policlinico Umberto I), Ida Paris(Agostino Gemelli University Polyclinic), Luís Orlando(Ospedale A. Perrino), Michela Piezzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), A. Fabi, Luigia Stefania Stucci, Alfredo Guarino(Federico II University Hospital), Nicoletta Staropoli(Magna Graecia University), Masaya Sano(Takeda (Japan)), Giuseppe Buono(Federico II University Hospital), Giuseppina Rosaria Rita Ricciardi, S. Turano, Claudia von Arx(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Saverio Cinieri(Ospedale A. Perrino)
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282